Compare DIBS & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIBS | PLYX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.8M | 112.7M |
| IPO Year | 2021 | 2025 |
| Metric | DIBS | PLYX |
|---|---|---|
| Price | $4.39 | $1.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.00 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 111.8K | 26.4K |
| Earning Date | 11-05-2026 | 11-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.45 | ★ 77.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $89,620,000.00 | N/A |
| Revenue This Year | $2.10 | N/A |
| Revenue Next Year | $0.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.54 | N/A |
| 52 Week Low | $3.03 | $1.83 |
| 52 Week High | $6.62 | $10.93 |
| Indicator | DIBS | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 42.92 |
| Support Level | $3.82 | $1.87 |
| Resistance Level | $4.38 | $2.18 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 85.57 | 34.37 |
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.